Moreover, preclinical studies suggest that anti-VEGF therapies may reduce primary tumor growth but paradoxically promote tumor invasiveness and metastasis by increasing intratumoral hypoxia and HIF-1 activity [40]. The gene discussed is HIF1A; the disease is neoplasm.